Anaveon Achieves Phase 1 Clinical Benefit Signal for ANV600 as Company Seeks Oncology Partners

For potential development partners evaluating late-stage oncology assets, Anaveon's EXPAND-1 Phase 1 data for ANV600 (sunekafusp alpha), presented at the 2026 ASCO Annual Meeting on May 30, arrives alongside an active out-licensing process, raising immediate CMC and process validation questions for any organisation considering acquisition or co-development.

ANV600 is a first-in-class, non-blocking PD-1-targeted IL-2R-βγ agonist designed to selectively expand tumor-reactive PD-1+ CD8+ effector T cells. The mechanism targets a long-standing limitation of IL-2 therapy: systemic toxicity. EXPAND-1 enrolled patients with advanced solid tumors, including a cohort previously progressing on checkpoint inhibitor (CPI) therapy, a population with limited remaining options under current standard of care.

Key efficacy readouts from the poster (Abstract 2587) include a complete response in one NSCLC patient receiving ANV600 monotherapy at 120 µg/kg Q2W, partial responses in two patients on combination dosing with pembrolizumab, and disease control rates of 42% for monotherapy and 59% for the combination arm. Target lesion shrinkage was observed in 29% of monotherapy patients and 24% of combination patients. The recommended Phase 2 dose was established at 90 µg/kg weekly for four weeks, followed by 150 µg/kg Q2W. Pharmacodynamic data showed increased absolute counts of CD8+ T cells and NK cells relative to regulatory T cells, consistent with the proposed mechanism.

Principal investigator Prof. Dr. med. Markus Jörger of Health Ostschweiz noted that approximately 24% of patients achieved a complete response, partial response, or durable stable disease maintained for at least 18 weeks across three or more tumor assessments. The trial enrolled patients whose disease had progressed beyond available therapies, adding weight to the safety-efficacy profile observed.

Anaveon pivoted strategically to autoimmune and inflammatory disease earlier this year, repositioning its PD-1-targeted cytokine platform toward immunology. The oncology portfolio, including ANV600 and preclinical asset ANV700, is now being offered to global development and commercialization partners. For any incoming partner, the CMC transfer package, existing manufacturing process characterisation data, and comparability protocols will be central to due diligence; the established Phase 2 dose regimen provides a defined starting point for process validation planning under ICH Q10 and relevant 21 CFR Part 211 requirements.

CEO Thaminda Ramanayake cited strong interest from current clinical investigators and positioned ANV600 as suited for a partner with resources to advance it in CPI-resistant NSCLC and broader immuno-oncology indications.

The completeness of the existing CMC package and the depth of PK/PD characterisation transferred to any incoming partner will be the measurable checkpoint determining how quickly EXPAND-1 data can translate into a Phase 2 programme.

Source: Anaveon via GlobeNewswire, May 28, 2026. ASCO poster presentation scheduled Hall A, May 30, 2026, 1:30–4:30 pm CDT.